BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 24662245)

  • 1. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
    Mar BG; Bullinger LB; McLean KM; Grauman PV; Harris MH; Stevenson K; Neuberg DS; Sinha AU; Sallan SE; Silverman LB; Kung AL; Lo Nigro L; Ebert BL; Armstrong SA
    Nat Commun; 2014 Mar; 5():3469. PubMed ID: 24662245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CREBBP mutations in relapsed acute lymphoblastic leukaemia.
    Mullighan CG; Zhang J; Kasper LH; Lerach S; Payne-Turner D; Phillips LA; Heatley SL; Holmfeldt L; Collins-Underwood JR; Ma J; Buetow KH; Pui CH; Baker SD; Brindle PK; Downing JR
    Nature; 2011 Mar; 471(7337):235-9. PubMed ID: 21390130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.
    Xiao H; Wang LM; Luo Y; Lai X; Li C; Shi J; Tan Y; Fu S; Wang Y; Zhu N; He J; Zheng W; Yu X; Cai Z; Huang H
    Oncotarget; 2016 Jan; 7(3):2696-708. PubMed ID: 26527318
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Contreras Yametti GP; Robbins G; Chowdhury A; Narang S; Ostrow TH; Kilberg H; Greenberg J; Kramer L; Raetz E; Tsirigos A; Evensen NA; Carroll WL
    Leuk Lymphoma; 2024 Jan; 65(1):78-90. PubMed ID: 37874744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation-sequencing of recurrent childhood high hyperdiploid acute lymphoblastic leukemia reveals mutations typically associated with high risk patients.
    Chen C; Bartenhagen C; Gombert M; Okpanyi V; Binder V; Röttgers S; Bradtke J; Teigler-Schlegel A; Harbott J; Ginzel S; Thiele R; Husemann P; Krell PF; Borkhardt A; Dugas M; Hu J; Fischer U
    Leuk Res; 2015 Sep; 39(9):990-1001. PubMed ID: 26189108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes.
    Huether R; Dong L; Chen X; Wu G; Parker M; Wei L; Ma J; Edmonson MN; Hedlund EK; Rusch MC; Shurtleff SA; Mulder HL; Boggs K; Vadordaria B; Cheng J; Yergeau D; Song G; Becksfort J; Lemmon G; Weber C; Cai Z; Dang J; Walsh M; Gedman AL; Faber Z; Easton J; Gruber T; Kriwacki RW; Partridge JF; Ding L; Wilson RK; Mardis ER; Mullighan CG; Gilbertson RJ; Baker SJ; Zambetti G; Ellison DW; Zhang J; Downing JR
    Nat Commun; 2014 Apr; 5():3630. PubMed ID: 24710217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
    Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
    Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
    Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
    Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards an understanding of the biology and targeted treatment of paediatric relapsed acute lymphoblastic leukaemia.
    Irving JA
    Br J Haematol; 2016 Mar; 172(5):655-66. PubMed ID: 26568036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia.
    Xu H; Yu H; Jin R; Wu X; Chen H
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the inhibitors of histone-lysine N-methyltransferase SETD2 for acute lymphoblastic leukaemia from traditional Chinese medicine.
    Chang YL; Chen HY; Chen KB; Chen KC; Chang KL; Chang PC; Chang TT; Chen YC
    SAR QSAR Environ Res; 2016 Jul; 27(7):589-608. PubMed ID: 27218135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia.
    Zhu YM; Foroni L; McQuaker IG; Papaioannou M; Haynes A; Russell HH
    Br J Cancer; 1999 Mar; 79(7-8):1151-7. PubMed ID: 10098750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia.
    Inthal A; Zeitlhofer P; Zeginigg M; Morak M; Grausenburger R; Fronkova E; Fahrner B; Mann G; Haas OA; Panzer-Grümayer R
    Leukemia; 2012 Aug; 26(8):1797-803. PubMed ID: 22388726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
    Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia.
    Kawamura M; Kikuchi A; Kobayashi S; Hanada R; Yamamoto K; Horibe K; Shikano T; Ueda K; Hayashi K; Sekiya T
    Blood; 1995 May; 85(9):2546-52. PubMed ID: 7727782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia.
    Emerenciano M; Barbosa Tda C; de Almeida Lopes B; Meyer C; Marschalek R; Pombo-de-Oliveira MS
    Br J Haematol; 2015 Jul; 170(2):268-71. PubMed ID: 25613690
    [No Abstract]   [Full Text] [Related]  

  • 17.
    Mar BG; Chu SH; Kahn JD; Krivtsov AV; Koche R; Castellano CA; Kotlier JL; Zon RL; McConkey ME; Chabon J; Chappell R; Grauman PV; Hsieh JJ; Armstrong SA; Ebert BL
    Blood; 2017 Dec; 130(24):2631-2641. PubMed ID: 29018079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by
    Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupéré-Richér D; Roth JS; Jing D; Casellas Román HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD
    Cancer Discov; 2022 Jan; 12(1):186-203. PubMed ID: 34417224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
    Meyer JA; Wang J; Hogan LE; Yang JJ; Dandekar S; Patel JP; Tang Z; Zumbo P; Li S; Zavadil J; Levine RL; Cardozo T; Hunger SP; Raetz EA; Evans WE; Morrison DJ; Mason CE; Carroll WL
    Nat Genet; 2013 Mar; 45(3):290-4. PubMed ID: 23377183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of functional cooperative mutations of SETD2 in human acute leukemia.
    Zhu X; He F; Zeng H; Ling S; Chen A; Wang Y; Yan X; Wei W; Pang Y; Cheng H; Hua C; Zhang Y; Yang X; Lu X; Cao L; Hao L; Dong L; Zou W; Wu J; Li X; Zheng S; Yan J; Zhou J; Zhang L; Mi S; Wang X; Zhang L; Zou Y; Chen Y; Geng Z; Wang J; Zhou J; Liu X; Wang J; Yuan W; Huang G; Cheng T; Wang QF
    Nat Genet; 2014 Mar; 46(3):287-93. PubMed ID: 24509477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.